Compare
AbbVie vs Moderna (ABBV vs MRNA)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Moderna (MRNA) +978.9%; so far this year the figures are +27.5% and +762.0%.
AbbVie is the larger company by market value, about 5.0 times the size of Moderna.
Revenue grew +10.7% at ABBV and +13.1% at MRNA over the last year.
ABBV yields 2.38%. MRNA pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | MRNA | |
|---|---|---|
| Price | $291.31 | $254.19 |
| 1-day | +1.07% | +5.27% |
| YTD | +27.49% | +761.95% |
| 1 year | +34.39% | +978.90% |
| 3 years | +104.47% | +233.58% |
| Market cap | $514.9B | $102.8B |
| P/E | 50.1 | — |
| P/S | 7.80 | 40.73 |
| P/B | — | 15.04 |
| Revenue growth | +10.70% | +13.10% |
| EPS growth | +340.20% | — |
| Gross margin % | 73.7 | 28.0 |
| Net margin % | 15.7 | -110.5 |
| ROE % | — | -40.8 |
| Debt / equity | — | 0.09 |
| FCF yield % | 3.7 | -1.9 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 2.27 |
| RSI (14) | 59.7 | 63.7 |
| Technical rating |